Sequence variations in the FII, FV, F13A1, FGB and PAI-1 genes are associated with differences in myocardial perfusion

Pharmacogenomics

Volumn 12, Issue 2, 2011, Pages 195-203

  Satra, Maria ^a   Samara, Maria ^a   Wosniak, Greta ^a   Tzavara, Chara ^a   Kontos, Angelos ^a   Valotassiou, Varvara ^a   Vamvakopoulos, Nikolaos K ^a   Tsougos, Ioannis ^a   Aleporou Marinou, Vassiliki ^b   Patrinos, George P ^c   Kollia, Panagoula ^b   Georgoulias, Panagiotis ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c National and Kapodistrian University of Athens ^*

Author keywords

coronary artery disease; FGB; FII; FV; FXIII gene polymorphism; myocardial; PAI 1; single photon emission computed tomography; SPECT

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5 LEIDEN; CALCIUM CHANNEL BLOCKING AGENT; FIBRINOGEN; NITRATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR 1; TETROFOSMIN TC 99M; UNCLASSIFIED DRUG;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; EXERCISE TEST; FAMILY HISTORY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEART MUSCLE PERFUSION; HEART RATE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PREDICTION; PROGNOSIS; SEQUENCE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS; CORONARY ARTERY DISEASE; EXERCISE TEST; FACTOR V; FACTOR XIII; FEMALE; FIBRINOGEN; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN;

EID: 79951893957     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.180     Document Type: Article

References (54)

1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349, 1498-1504 (1997).
2. Roberts R: A customized genetic approach to the number one killer: coronary artery disease. Curr. Opin. Cardiol. 23, 629-633 (2008).
3. Ross R: Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
4. Zaman AG, Helft G, Worthley SG et al.: The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149, 251-266 (2000).
5. Ardissino BY, Mannucci PM, Mertini PA et al.: Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 94, 46-51 (1999).
6. Voetsch B, Loscalzo J: Genetic determinants of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 24, 216-229 (2004).
7. Watkins H, Farrall M: Genetic susceptibility to coronary artery disease: from promise to progress. Nat. Rev. Genet. 7, 163-173 (2006).
8. Ye Z, Liu EH, Higgins JP et al.: Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 367, 651-658 (2006).
9. Iacoviello L, Di Castelnuovo A, De Knijff P et al.: Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N. Engl. J. Med. 338, 79-85 (1998).
10. Lane A, Green F, Scarabin PY et al.: Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 119, 119-127 (1996).
11. Georgoulias P, Wozniak G, Samara M et al.: Impact of ACE and ApoE polymorphisms on myocardial perfusion: correlation with myocardial single photon emission computed tomographic imaging. J. Hum. Genet. 54, 595-602 (2009). First evidence of an association of ACE and ApoE polymorphisms with myocardial perfusion, which suggests that the proposed effect of the abovementioned polymorphisms may have important influence on early patient risk stratification.
12. Russell RR, Zaret LB: Nuclear cardiology: present and future. Curr. Probl. Cardiol. 31, 557-629 (2006). Presents the significant diagnostic and prognostic value of nuclear cardiology techniques and more specifically, the role of molecular imaging in early detection of coronary artery disease (CAD) and monitoring of important new therapies.
13. van't Hooft FM, von Bahr SJ, Silveira A et al.: Two common, functional polymorphisms in the promoter region of the β-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler. Thromb. Vasc. Biol. 19, 3063-3070 (1999).
14. Bertina RM, Koeleman BP, Koster T et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64-67 (1994).
15. Poort SR, Rosendaal FR, Reitsma PH et al.: A common genetic variation in the 39-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88, 3698-3703 (1996).
16. Dawson SJ, Wiman B, Hamsten A et al.: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem. 268, 10739-10745 (1993).
17. Balogh I, Szoke G, Karpati L et al.: Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 96, 2479-2486 (2000).
18. Lim BC, Ariens RA, Carter AM et al.: Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 361, 1424-1431 (2003).
19. Georgoulias P, Demakopoulos N, Orfanakis A et al.: Evaluation of abnormal heart-rate recovery after exercise testing in patients with diabetes mellitus: correlation with myocardial SPECT and chronotropic parameters. Nucl. Med. Commun. 28, 165-171 (2007).
20. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215-1216 (1988).
21. Fletcher GF, Balady G, Froelicher VF et al.: Exercise standards. A statement for healthcare professionals from the American Heart Association Writing Group. Circulation 91, 580-615 (1995).
22. Georgoulias P, Orfanakis A, Demakopoulos N et al.: Abnormal heart rate recovery immediately after treadmill testing: correlation with clinical, exercise testing, and myocardial perfusion parameters. J. Nucl. Cardiol. 10, 498-505 (2003).
23. Kapur A, Latus KA, Davies G et al.: A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur. J. Nucl. Med. 29, 1608-1616 (2002).
24. Wackers FJT: Clinical Nuclear Cardiology. State of the Art and Future Directions. Zarret BL, Beller GA (Eds). Elsevier Mosby, PA, USA, 221-223 (2005).
25. Mikkola H, Syrjala M, Rasi V et al.: Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 84, 517-525 (1994).
26. Vokó Z, Bereczky Z, Katona E et al.: Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. Thromb. Haemost. 97, 458-463 (2007). Demonstrated that the FXIII-A p.V34L polymorphism exerts a protective effect against CAD, supported by a meta-analysis.
27. Bereczky Z, Balogh E, Katona E et al.: Decreased factor XIII levels in factor XIII A subunit Leu34 homozygous patients with coronary artery disease. Thromb. Res. 121, 469-476 (2008).
28. Bronic A, Ferencak G, Zadro R et al.: Impact of FXIII-A Val34Leu polymorphism on coronary artery disease in Croatian patients. Mol. Biol. Rep. 36, 1-5 (2009).
29. Roldan V, Corral J, Marin F et al.: Role of factor XIII Val34Leu polymorphismin patients b45 years of age with acute myocardial infarction. Am. J. Cardiol. 91, 1242-1245 (2003).
30. Butt C, Zheng H, Randell E et al.: Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood 101, 3037-3041 (2003).
31. Ercan B, Tamer L, Sucu N et al.: Factor V leiden and prothrombin G20210A gene polymorphisms in patients with coronary artery disease. Yonsei Med. J. 49, 237-243 (2008).
32. Corral J, Gonzalez-Conjero R, Lozano ML et al.: The venous thrombosis risk factor 20210A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br. J. Haematol. 99, 304-307 (1997).
33. Watzke HH, Schüttrumpf J, Graf S et al.: Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. Thromb. Res. 87, 521-526 (1997).
34. De Stefano V, Chiusolo P, Paciaroni K et al.: Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 91, 3562-3565 (1998).
35. Rosendaal FR, Siscovick DS, Schwartz SM et al.: A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 90, 1747-1750 (1997).
36. Rosendaal FK, Siscovick DS, Schwartz SM et al.: Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89, 2817-2821(1997).
37. Holm J, Zoeller B, Berntorp E et al.: Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J. Intern. Med. 239, 221-226 (1996).
38. Petrovic D, Zorc M, Keber I et al.: Joint effect of G1691A factor V point mutation and factor VII Arg/Gln(353) gene polymorphism on the risk of premature coronary artery disease. Ann. Genet. 44, 33-36 (2001). Sought an association between the FV g.G1691A and FVII p.R353Q variations and premature CAD. The study also assessed the interactive effect on CAD risk between the two abovementioned variations as well as between tested polymorphisms and traditional risk factors.
39. Juul K, Tybjaerg-Hansen A, Steffensen R et al.: Factor V Leiden: The Copenhagen City Heart study and 2 meta-analyses. Blood 100, 3-10 (2002).
40. Gardemann A, Arsic T, Katz N et al.: The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. Thromb. Haemost. 81, 208-213 (1999).
41. Thompson SG, Kienast J, Pyke SD et al.: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European concerted action on thrombosis and disabilities angina pectoris study group. N. Engl. J. Med. 332, 635-641 (1995).
42. Koster T, Rosendaal FR, Reitsma PH et al.: Factor VII and fibrinogen levels as risk factors for venous thrombosis. Thromb. Haemost. 71, 719-722 (1994).
43. Banerjee AK, Pearson J, Gilliland EL et al.: A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb. Haemost. 68, 261-263 (1992).
44. de Maat MP, Kastelein JJ, Jukema JW et al.: 455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler. Thromb. Vasc. Biol. 18, 265-271 (1998).
45. Behague I, Poirier O, Nicaud V et al.: β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: the ECTIM study. Circulation 93, 440-449 (1996).
46. Swiatkiewicz A, Jurkowski P, Kotschy M et al.: A level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis. Med. Sci. Monit. 8, 263-268 (2002).
47. Anvari A, Schuster E, Gottsauner-Wolf M et al.: PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. Thromb. Res. 103, 103-107 (2001). Demonstrated that the -675 4G/5G polymorphism of the PAI-I gene is involved in CAD, with the highest risk in 4G homozygotes, that favored myocardial ischemia, even in the absence of acute infarction.
48. Juhan-Vague I, Morange PE, Frere C et al.: The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J. Thromb. Haemost. 1, 2322-2329 (2003).
49. Sarecka B, Zak I, Krauze J: Synergistic effects of the polymorphisms in the PAI-1 and IL-6 genes with smoking in determining their associated risk with coronary artery disease. Clin. Biochem. 41, 467-473 (2008).
50. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group: No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 107, 1117-1122 (2003).
51. Ding J, Nicklas BJ, Fallin MD et al.: Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am. Heart J. 152 1109-1115 (2006).
52. Petrovic D, Globocnik-Petrovic M, Peterlin B: 4G4G genotype of PAI-1 gene promoter polymorphism is not associated with myocardial infarction in Caucasians with Type-2 diabetes. Cardiology 100, 157-158 (2003).
53. Bastard JP, Pieroni L: Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed. Pharmacother. 53, 455-461 (1999).
54. Margaglione M, Cappucci G, d'Addedda M et al.: PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler. Thromb. Vasc. Biol. 18, 562-567 (1998).